Construction management services

Tender description

This is Amendment to the original PIN Estimation of Value of Works should read 9 000 000 GBP — 11 000 000 GBP. With Phase 1 due to complete mid 2017, there is a business need to increase the number of modules within the facility from the 6nr completed as part of Phase 1 to 12nr (Phase 2). Expressions of interest are sought from suitably qualified contractors responding to this SQ PQQ, who will need to demonstrate experience in successfully delivering the fit out of complex, GMP biologics manufacturing projects of the scale and to the programme required for this Project. Cell & Gene Therapy intends to appoint a combined project management and design team to work with CGT to deliver the proposed Phase 2 of the Project. The Client is looking for contractors who: — are financially sound; — have suitable technical skills in respect of design, programming fast-track projects, coordination and integration of design and construction-related activities; — have, together with their proposed supply chain sub-contractors and suppliers, specific expertise, experience and skills in delivering projects of a similar nature to the CGT requirement involving the design, commissioning and successful handover; 2 / 4 — possess the necessary skills to obtain and implement any required statutory approvals; — possess an exceptional health and safety record — our requirement is reflected in the allocated weightings for the questions relating to health and safety within this SQ; — have managed the design and construction process to deliver similar projects to at least an ‘Very Good’ BREEAM standard; — are familiar with, and have experience in working to BIM Level 2; — can provide evidence of their expertise and a proven commitment to delivery within agreed programmes, costs, quality and, most importantly, focused delivery to meet client objectives. The concept design is currently being developed but the requirement is likely to involve the following as progressed but is likely to include: — The fit out of approximately 3 000 m2. In addition, there will be an interstitial plant ceiling above the module ceiling plate; — Flexible configuration Grade C Clean room space suitable for Advanced Therapy Medicinal Product manufacture, with the ability to deliver multiple parallel processes for Autologous product manufacturing, and the flexibility to convert the clean spaces to manufacture either Allogeneic products at up to 1 000 L scale, gene modified products or regenerative organs. The clean rooms will also have the flexibility for conversion between Grade C and Grade D classifications; — Potential extension to the existing warehouse and QC facility; — Completion of external works and access road (held over from Phase 1); — Works completed in an occupied building; — It must achieve the requisite licences for GMP manufacturing from the MHRA and be capable of meeting all regulatory requirements in significant markets worldwide, including US FDA cGMPs. — It will be based on the Manufacturing module principle developed at the Cell and Gene Therapy Catapult with additional flexible support space.